Suplmnt
Best supplements for liver health hero image
Best Supplements for liver health

Top 10 Evidence-Based Recommendations

Evidence Level: promisingRanking methodology

We analyzed 60+ human trials and meta-analyses on liver-targeted supplements—prioritizing histology, liver fat and ALT/AST changes, safety, and practicality. No fluff, no affiliate links—just what actually moved the needle in RCTs. [1][2][3][4][5]

Quick Reference Card

1.Silybin phytosome (milk thistle) 160–240 mg, 2×/day. [2][4]
2.Omega-3 EPA/DHA 2–4 g/day. [5]
3.Berberine 500 mg, 2–3×/day. [7]
4.Delta-tocotrienol 300 mg, 2×/day. [8]
5.Vitamin E 800 IU/day (non-diabetic NASH only, supervised). [1]
6.Probiotics 10⁹–10¹⁰ CFU/day. [12]
Show all 10 supplements...
7.Coffee 2–3 cups/day. [15]
8.CoQ10 100–240 mg/day. [16][18]
9.Curcumin 500–1,000 mg/day (enhanced forms). [19][21]
10.Phosphatidylcholine 1.2–2.4 g/day. [22]

Ranked Recommendations

#1Top Choice

Old herb, new tech: the phytosome form is the quiet heavyweight for liver enzymes and histology.

Dose: Silybin phytosome 160–240 mg, 2×/day with meals; some trials used combo with vitamin E for 12 months.

Time to Effect: 8–12 weeks for ALT/AST; 6–12 months for imaging/histology.

How It Works

Standard silymarin is poorly absorbed. Complexing silybin with phosphatidylcholine (phytosome) boosts bioavailability and concentrates antioxidant, membrane-stabilizing, and antifibrotic actions in hepatocytes. This can lower transaminases and improve steatosis scores on biopsy. [2][4]

Evidence

Meta-analyses of RCTs show silymarin reduces ALT/AST, with a 2024 review (26 RCTs, n≈2,375) also reporting improved steatosis indices and better odds of histologic steatosis improvement. A 12-month RCT of silybin phytosome + vitamin E improved enzymes, HOMA-IR, and liver histology vs placebo. One high-dose silymarin trial in biopsy-proven NASH missed its primary endpoint but suggested fibrosis score benefits. Overall: consistent enzyme drops; histology signals strongest with phytosome formulations and longer use. [4][2][3]

Best for:NAFLD/MASH with elevated ALT/AST; those wanting non-pharmacologic options alongside diet/exercise.

Caution:Occasional GI upset/itching; choose reputable brands to avoid adulteration.

Tip:Look for "silybin phytosome," "siliphos," or "phospholipid complex." Plain silymarin 140 mg tabs aren't equivalent.

#2Strong Alternative

The fat that helps your liver lose fat.

Dose: 2–4 g/day combined EPA+DHA with food.

Time to Effect: 8–12 weeks for ALT/AST and liver fat.

How It Works

Omega-3s remodel hepatic lipid handling, lowering de novo lipogenesis and triglyceride export burden; they also resolve low-grade inflammation—together reducing liver fat and enzymes. [5]

Evidence

Umbrella/meta-analyses (6,500+ participants) show meaningful reductions in ALT (≈−6–7 IU/L), AST, GGT, and liver fat (CAP/MRI). Effects are dose-responsive and additive to lifestyle change. [5][6]

Best for:NAFLD with high triglycerides or metabolic syndrome.

Caution:May increase bruising at high doses; check interactions if on anticoagulants.

Tip:Pick triglyceride-form or re-esterified TG oils with a labeled EPA+DHA total; aim for ≥2 g/day combined.

#3Worth Considering

Metabolic reset for liver and blood sugar—without a prescription.

Dose: 500 mg, 2–3×/day with meals (total 1–1.5 g/day).

Time to Effect: 4–8 weeks for ALT/AST and lipids.

How It Works

Activates AMPK, improving insulin sensitivity and reducing hepatic lipogenesis; also shifts gut microbiota toward lower endotoxin load. [7]

Evidence

Meta-analysis of 10 RCTs (n=811) shows moderate-to-large improvements in ALT/AST, GGT, triglycerides, LDL-C, and HOMA-IR with mostly mild GI side effects. [7]

Best for:NAFLD with insulin resistance, elevated TG/LDL, prediabetes.

Caution:Can interact with cyclosporine, tacrolimus, and some statins; may cause GI upset.

Tip:Berberine HCl or berberine from Coptis/Berberis are fine; consistency > brand. Split doses to improve tolerance.

Loading products...

#4

The under-the-radar vitamin E that beat alpha-tocopherol head-to-head.

Dose: 300 mg δ‑tocotrienol, 2×/day with food (24–48 weeks in trials).

Time to Effect: 8–12 weeks for enzymes; 24+ weeks for steatosis indices.

How It Works

Tocotrienols embed in hepatocyte membranes, dampen NF-κB signaling, and improve lipid handling—distinct from standard alpha-tocopherol. [8]

Evidence

Placebo-controlled RCT (n=71) showed significant drops in ALT/AST, HOMA-IR, CRP, and improved ultrasound steatosis. A 48-week active-controlled RCT found δ-tocotrienol outperformed α-tocopherol on fatty liver and metabolic markers. [8][9]

Best for:Patients wanting an antioxidant option without high-dose alpha-tocopherol.

Caution:Generally well-tolerated; choose third-party tested products.

Tip:Look for annatto-derived δ/γ-tocotrienols; avoid stacking with high-dose alpha-tocopherol (may blunt effects).

#5

One of the few supplements that improved NASH on biopsy—used selectively.

Dose: 800 IU/day natural α‑tocopherol for up to 96 weeks (medical supervision).

Time to Effect: 12–24 months (histology); 12–24 weeks for enzymes.

How It Works

Antioxidant that reduces lipid peroxidation and hepatocellular injury in NASH. [1]

Evidence

PIVENS trial (n=247) showed 43% NASH improvement vs 19% placebo over 96 weeks in non-diabetic adults; no fibrosis improvement. Safety is debated: older meta-analyses signaled possible mortality risk at ≥400 IU/d, while others in healthy populations showed neutral mortality; discuss risks/benefits. [1][10][11]

Best for:Non-diabetic adults with biopsy-proven NASH under clinician care.

Caution:High-dose E may raise hemorrhagic stroke risk and has conflicting mortality data; not advised in diabetics or those with prostate cancer risk without physician oversight. [10][11]

Tip:If you qualify for vitamin E, don't combine with other high-dose E sources; reassess need at 6–12 months.

#6

Fix the gut–liver axis to calm the liver.

Dose: Multi‑strain Lactobacillus/Bifidobacterium blends, 10⁹–10¹⁰ CFU/day for ≥8–12 weeks; synbiotics add prebiotic fiber.

Time to Effect: 8–12 weeks for ALT/AST; sometimes earlier for bloating.

How It Works

Modulate gut permeability and endotoxin load, reducing hepatic inflammation and improving insulin sensitivity. [12]

Evidence

Meta-analyses of RCTs show reductions in ALT/AST and improved steatosis scores; benefits also seen in pediatric NAFLD. [12][13]

Best for:People with NAFLD plus GI symptoms or dysbiosis risk (antibiotics, low-fiber diet).

Caution:Temporary gas; immunocompromised patients should consult clinicians.

Tip:Pick defined-strain products with CFU guarantees through expiry; pair with 10–15 g/day fiber.

#7

Your daily cup is antifibrotic.

Click to expand details...

#8

Mitochondrial tune-up for a fatty liver.

Click to expand details...

#9

Inflammation down, liver ultrasound up—results vary by formulation.

Click to expand details...

#10

If you're short on choline, your liver pays the price.

Click to expand details...

Timeline Expectations

Fast Results

  • Omega-3 EPA/DHA 2–4 g/day (8–12 weeks). [5]
  • Berberine 1–1.5 g/day with meals (4–8 weeks). [7]
  • Coffee 2–3 cups/day (long-term antifibrotic signal). [15]

Gradual Benefits

  • Silybin phytosome (6–12 months for histology). [2][4]
  • Delta-tocotrienol (24–48 weeks). [8][9]
  • Vitamin E 800 IU/day (selected non-diabetic NASH; 96 weeks). [1]

Combination Strategies

Metabolic & Liver‑Fat Stack

Components: Berberine 500 mg with meals, 2–3×/day + Omega‑3 (EPA+DHA) 2–3 g/day + Multi‑strain probiotic 10⁹–10¹⁰ CFU/day

Targets insulin resistance (berberine), hepatic fat handling (omega-3), and gut-liver endotoxin load (probiotic) for additive ALT/AST and liver-fat reductions seen across RCTs/meta-analyses. [5][7][12]

Start probiotic week 1, add omega‑3 week 2, then berberine week 3 to gauge tolerance. Recheck lipids and ALT/AST at 12 weeks.

Antioxidant–Hepatoprotection Stack

Components: Silybin phytosome 160–240 mg, 2×/day + Delta‑tocotrienol 300 mg, 2×/day + CoQ10 100–200 mg/day with meals

Combines membrane stabilization/antifibrotic effects (silybin) with anti-inflammatory tocotrienols and mitochondrial support (CoQ10) for broader coverage than any single agent. RCTs show enzyme and steatosis improvements for each. [2][8][16]

All with meals. Give 8–12 weeks before judging; continue 6–12 months if improving.

Clinician‑Supervised NASH Adjunct

Components: Vitamin E (alpha‑tocopherol) 800 IU/day + Silybin phytosome 160–240 mg, 2×/day

Vitamin E improved NASH on biopsy in non-diabetic adults; phytosomal milk thistle has enzyme/histology signals—together may support histologic goals while awaiting/alongside lifestyle therapy. Use only under medical supervision due to vitamin E risk debate. [1][2][4]

Medical oversight required; reassess at 6 and 12 months; avoid other high‑dose vitamin E sources.

Shopping Guide

Form Matters

  • Milk thistle: choose silybin phytosome/siliphos, not plain silymarin. [2][4]
  • Omega-3: dose by grams of EPA+DHA (not "fish oil"); TG/re-esterified forms absorb best. [5]
  • Curcumin: phytosomal, nano-curcumin, or with piperine for absorption. [19]
  • Probiotics: labeled strains + CFU through expiry; avoid vague "proprietary blends." [12]
  • Vitamin E: δ-tocotrienol ≠ α-tocopherol; they're different. Use α-tocopherol only if you fit NASH criteria. [1][8]

Quality Indicators

  • 3rd-party testing (USP, NSF, Informed Choice).
  • Clear per-cap dose of actives (e.g., EPA+DHA grams).
  • Lot/batch COAs; GMP-certified manufacturing.

Avoid

  • Proprietary blends without doses.
  • 'Liver detox' claims with laxatives/diuretics masquerading as results.
  • Megadose vitamin E stacks (≥400 IU) without a clear medical indication. [10][11]

Overrated Options

These supplements are often marketed for liver health but have limited evidence:

Ursodeoxycholic acid (UDCA)/TUDCA for NAFLD

Multiple RCTs (standard and high-dose) failed to improve histology vs placebo in NASH; enzyme drops did not translate to meaningful outcomes. Save your money unless prescribed for gallstones/cholestatic disease. [23][24][25]

N‑acetylcysteine (NAC) for NAFLD

Compelling mechanisms and animal data, but human evidence is limited/combination or open-label trials; not a top pick for liver fat or histology yet. [20][27]

Green tea extract capsules

Mixed metabolic effects and a recognized hepatotoxicity signal with concentrated EGCG bolus doses (especially fasting). Brewed tea is fine; avoid high-dose extracts for "liver detox." [28][29]

Important Considerations

If you have cirrhosis, cholestatic disease, are pregnant, or take anticoagulants/immunosuppressants, talk to your clinician before starting supplements. Avoid combinations that duplicate vitamin E. Re-test ALT/AST, lipids, and, if possible, liver fat (CAP) at 12–24 weeks to confirm benefit.

How we chose these supplements

We prioritized human RCTs/meta-analyses with hard endpoints (liver fat by CAP/MRI, histology; then ALT/AST). We weighted effect size, risk of bias, safety, cost, and practicality. Where evidence conflicted (e.g., curcumin, vitamin E safety), we reported both sides and ranked accordingly. [1][4][5][19][21]

Common Questions

What’s the single best supplement for fatty liver?

If I had to pick one: silybin phytosome, thanks to enzyme and histology signals in RCTs. Pair it with omega-3s for liver fat. [2][4][5]

How long before I see results?

Most see ALT/AST shifts in 8–12 weeks; liver fat/histology take 3–12 months. Recheck labs at 12 weeks.

Can supplements reverse fatty liver without diet?

They help, but weight loss (7–10%) still delivers the biggest liver fat and NASH benefits. Use supplements as add-ons, not substitutes.

Is milk thistle just hype?

Plain silymarin is underwhelming; silybin phytosome is the form with the best human data. [2][4]

Is vitamin E safe for liver disease?

It helped non-diabetic NASH in PIVENS, but high-dose E has debated risks. Use only if you fit criteria and your clinician agrees. [1][10][11]

Do probiotics actually help the liver?

Yes—meta-analyses of RCTs show ALT/AST reductions and steatosis improvements, likely via the gut-liver axis. [12][13]

Sources

  1. 1.
    Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (PIVENS) (2010) [link]
  2. 2.
    Silybin phytosome + vitamin E in NAFLD: randomized controlled trial (2012) [link]
  3. 3.
    A Randomized Trial of Silymarin for the Treatment of NASH (2017) [link]
  4. 4.
    Administration of silymarin in NAFLD/NASH: systematic review & meta‑analysis (26 RCTs) (2024) [link]
  5. 5.
    Omega‑3 PUFA for NAFLD: umbrella systematic review & meta‑analysis (2023) [link]
  6. 6.
    Effectiveness of Omega‑3 in NAFLD: systematic review & meta‑analysis (2018–2023) (2024) [link]
  7. 7.
    Berberine for NAFLD: meta‑analysis of randomized trials (2024) [link]
  8. 8.
    Δ‑tocotrienol RCT in NAFLD (24 weeks) (2020) [link]
  9. 9.
    δ‑Tocotrienol vs α‑tocopherol (48‑week RCT) (2022) [link]
  10. 10.
    Meta‑analysis: high‑dose vitamin E and mortality risk (2005) [link]
  11. 11.
    Vitamin E supplementation and mortality in healthy people: meta‑analysis (2014) [link]
  12. 12.
    Probiotics for NAFLD: systematic review & meta‑analysis of RCTs (2021) [link]
  13. 13.
    Probiotics in pediatric NAFLD: meta‑analysis of RCTs (2022) [link]
  14. 14.
    Coffee RCT meta‑analysis: adiponectin increase, no enzyme change (2022) [link]
  15. 15.
    Coffee intake and NAFLD: observational meta‑analysis (2021) [link]
  16. 16.
    CoQ10 RCT in NAFLD (12 weeks, 100 mg/day) (2015) [link]
  17. 17.
    CoQ10 in NAFLD: systematic review & meta‑analysis of RCTs (2023) [link]
  18. 18.
    CoQ10 in MASLD: 6‑month RCT (240 mg/day) (2024) [link]
  19. 19.
    Curcumin as adjunct in NAFLD: systematic review & meta‑analysis (2022) [link]
  20. 20.
    N‑acetylcysteine in NAFLD: preclinical meta‑analysis (2023) [link]
  21. 21.
    Curcumin in NAFLD: 2024 clinical meta‑analysis (null overall) (2024) [link]
  22. 22.
    Phosphatidylcholine (choline) RCT in NAFLD (12 weeks) (2025) [link]
  23. 23.
    UDCA for NASH: randomized trial (no benefit on histology) (2004) [link]
  24. 24.
    High‑dose UDCA (23–28 mg/kg) RCT (2010) [link]
  25. 25.
    High‑dose UDCA multicenter RCT (28–35 mg/kg) (2011) [link]
  26. 26.
    Phosphatidylcholine pilot (Essentiale) (2022) [link]
  27. 27.
    NAC ± UDCA + metformin in NASH: open‑label randomized multicenter (2019) [link]
  28. 28.
    Green tea (GTE) hepatotoxicity overview (LiverTox) (2019) [link]
  29. 29.
    Green tea safety systematic review (EGCG thresholds) (2018) [link]